Advertisements

Кардосал 10

Quick links to important sections

Кардосал 10

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Кардосал 10

What is Кардосал 10? Defining the Antihypertensive Agent

Property Description
Active ingredient Olmesartan Medoxomil (Prodrug)
Form Oral Film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common purpose Management of high blood pressure (Hypertension)
Origin Synthetic compound

What Type of Medicine is Кардосал 10?

Кардосал 10 is a prescription-only medication whose active component is Olmesartan Medoxomil, a synthetic compound officially classified as an Angiotensin II Receptor Blocker (ARB). The overall purpose of this drug is the management of essential hypertension (high blood pressure). It acts systemically to ease the cardiovascular workload by modulating a key regulatory pathway. The compound is widely and clinically recognized for its efficacy in achieving target blood pressure levels in patients requiring chronic antihypertensive therapy.

Olmesartan Medoxomil: Composition and Form

The core component of Кардосал 10 is the International Nonproprietary Name (INN) substance, Olmesartan Medoxomil. Chemically, this is a synthetic prodrug that is rapidly converted to its pharmacologically active metabolite, Olmesartan, during absorption from the gastrointestinal tract. This prodrug feature is a distinguishing characteristic, ensuring that the medication is efficiently absorbed before it becomes fully active.

The medicine is supplied for oral administration in the form of a film-coated tablet, a stable single-ingredient preparation designed for systemic action. As a single-ingredient formulation, its therapeutic identity is focused solely on the action of its primary compound.

How Does the ARB Class Achieve Blood Pressure Reduction?

The mechanism of action for Кардосал 10 is a direct and targeted selective blockade of the AT1 receptor, which is the site where the hormone Angiotensin II binds to cause blood vessels to tighten. By blocking the receptor, the medication essentially removes the signal that instructs blood vessels to narrow. This blockade causes the blood vessels to relax and widen, a process known as vasodilation, and results in a decreased systemic vascular resistance. This fundamental effect is the key mechanism by which the drug achieves its intended general benefit: a predictable, sustained reduction in blood pressure.

Regulatory References

  1. Olmesartan ARB Mechanism of Action (NIH/NCBI)
Advertisements

What side effects are possible with Кардосал 10?

Possible Side Effects and Safety Information

Regulatory documentation structures the safety profile of Кардосал 10 (Olmesartan Medoxomil) by classifying observed adverse reactions based on their frequency and the physiological system affected. The most frequently documented adverse effects are generally classified as Common and include events such as dizziness, headache, bronchitis, cough, diarrhea, and fatigue, as listed in official prescribing information.

Adverse effects are also categorized by the affected System-Organ Class (SOC), including reactions affecting the Nervous System (e.g., dizziness), the Gastrointestinal System (e.g., diarrhea, abdominal pain), and the Respiratory System (e.g., bronchitis, pharyngitis). Reactions classified as Uncommon or Rare include events like thrombocytopenia, anaphylactic reaction, angina pectoris, hypotension, hyperkalaemia, and acute renal failure.

Official labels highlight specific Serious Safety Concerns. Use during pregnancy is strictly contraindicated due to the risk of Fetal Toxicity (injury and death to the developing fetus). A specific, rare gastrointestinal condition known as Sprue-like enteropathy, characterized by severe, chronic diarrhea, is officially documented as developing potentially months to years after treatment initiation. Other serious events include Angioedema and Symptomatic Hypotension, which may be anticipated upon the start of therapy, especially in volume-depleted individuals.

Population-Specific Safety Constraints exist: the drug must not be used in children under one year of age, nor is it recommended in individuals with severe hepatic impairment. Furthermore, the official label restricts its use with Aliskiren in patients with diabetes or moderate-to-severe renal impairment, a critical limitation for dual RAAS inhibition.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Кардосал 10 (Olmesartan Medoxomil) strictly defines overdose based on the exaggerated consequences of its intended action, specifically severe low blood pressure.

Documented Overdose Presentations

The most likely and clinically significant manifestation of overdose is Excessive Hypotension (profoundly low blood pressure). Signs associated with this condition include dizziness, faintness, or severe lightheadedness. Other cardiac signs may include changes in heart rate, documented as Tachycardia (fast heartbeat) or, less commonly, Bradycardia (slow heartbeat).

Serious, life-threatening outcomes documented in the regulatory information include the potential for Acute Renal Failure in susceptible patients due to severe hypotension. There is also a stated risk of secondary complications, such as Myocardial Infarction or Cerebrovascular Accident, in patients with pre-existing ischemic disease during a severe hypotensive episode.

Required Emergency Action

Seek immediate emergency medical attention and contact a regional poison control center upon suspicion of overdose. Management is exclusively symptomatic and supportive. Regulatory procedures specify positioning the patient in the supine position and administering an intravenous infusion of normal saline for volume expansion if severe hypotension is present.

The active substance is considered not dialyzable, and no specific antidote is known. Close observation of blood pressure and renal function is required during management. Infants with in utero exposure represent a specific population requiring specialized monitoring for hypotension, oliguria, and hyperkalemia.

Advertisements

Therapeutic Uses of Кардосал 10

What Кардосал 10 Treats: Main Uses and Benefits

The therapeutic role of Кардосал 10 (Olmesartan Medoxomil) is generally focused on the long-term management of the clinical condition of hypertension and its associated downstream consequences.

The primary therapeutic goal is to help lower blood pressure, which may assist in reducing the risk of major cardiovascular events, such as strokes and heart attacks. This medication is fundamentally used for the sustained control of essential hypertension, supporting the heart's workload and contributing to stable cardiovascular functioning.

Кардосал 10 is considered relevant for managing blood pressure in several critical scenarios, including adults, geriatric patients with isolated systolic hypertension, and pediatric patients (aged 6 to 16 years). It is commonly applied in high-risk contexts where symptoms are related to systemic imbalance, such as in patients with coexisting Type 2 Diabetes and kidney issues. The key benefit is the long-term support it provides, assisting with the overall management of the condition by helping to reduce the potential for severe, future complications.

“It is commonly used to help with conditions marked by increased physiological stress and contributes to assisting with maintaining functional stability during symptomatic periods.”

The therapeutic indications for this agent include the chronic management of essential hypertension, the reduction of cardiovascular risk (stroke and heart attack), and providing supportive relief for the kidneys in diabetic patients with high blood pressure.


Quick Fact: Support for Cardiovascular Strain The medicine supports the body in assisting with maintaining functional stability by reducing the chronic physiological strain caused by high blood pressure.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Кардосал 10 (Olmesartan Medoxomil)

Official regulatory documents define specific populations for whom the use of this medicine is permitted, restricted, or prohibited.

Classification Eligible Population or Condition Regulatory Status
Approved Age Group Adults (18+ years) Use Established
Approved Age Group Pediatric patients aged 6 to 16 years Use Established
Organ Function Severe renal impairment (CrCl <20 mL/min) Not Recommended
Organ Function Moderate to severe hepatic impairment Not Recommended
Comorbidity Concomitant use with aliskiren in patients with diabetes mellitus Contraindicated
Physiological State Second and third trimesters of pregnancy Contraindicated
Hypersensitivity Known hypersensitivity to Olmesartan Medoxomil Contraindicated

Specific Population Restrictions

Absolute Prohibition: The medicine is contraindicated during the second and third trimesters of pregnancy; use must be stopped immediately when pregnancy is detected. It is also contraindicated for patients with hypersensitivity to the drug and for diabetic patients taking aliskiren.

Age-Related Limits: Children under 1 year of age must not receive this medication. For children aged 1 to 5 years, use is not established. Use is generally established for older adults, showing no overall difference in efficacy or safety relative to younger adults.

Conditional Use: Patients with pre-existing conditions such as volume or salt depletion must have this condition corrected prior to the administration of the medicine.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Olmesartan Medoxomil (Кардосал 10) details specific interaction constraints based on pharmacodynamic and pharmacokinetic effects, while noting a low likelihood of interactions involving the cytochrome P450 system.

Formal Restrictions and Contraindications

The co-administration of Olmesartan with Aliskiren is contraindicated in patients with Type 2 Diabetes Mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m^2). This restriction prevents severe outcomes associated with dual blockade of the Renin-Angiotensin System (RAAS).

Clinically Significant Interaction Patterns

Interacting Agent Official Interaction Outcome Regulatory Constraint
Potassium-sparing Diuretics / Supplements Increased risk of Hyperkalemia due to additive effects. Requires careful monitoring for potassium levels.
Lithium Reduced renal clearance, leading to increased serum Lithium concentrations and potential toxicity. Monitoring of Lithium levels is necessary.
Colesevelam Hydrochoride Reduces Olmesartan systemic exposure (AUC/Cmax). Must be administered 4 hours after Olmesartan.
NSAIDs Documented reduction of the antihypertensive effect and risk of worsening renal function. Interaction noted as clinically significant.

Кардосал 10 has no clinically relevant interaction with food, and its metabolic pathway is documented as non-reliant on the common CYP450 enzymes.

Advertisements

Mechanism of Action

How Кардосал 10 Works

Кардосал 10 (Olmesartan) operates by engaging in a targeted receptor blockade within the body's cardiovascular regulatory system. Its mechanism is centered on the Renin-Angiotensin-Aldosterone System (RAAS). The active ingredient functions as a highly selective antagonist by binding to the Angiotensin II type 1 ( AT1) receptors . This binding prevents the naturally occurring hormone Angiotensin II from activating the receptor. The resultant inhibition of the AT1 receptor reduces the systemic signals for vascular smooth muscle contraction and suppresses hormonal signaling that promotes sodium and water retention in the kidneys. The consequence of decreased vascular tone and reduced fluid retention signaling is a physiological decrease in the Peripheral Vascular Resistance. This core mechanistic change results in reduced force being exerted against the arterial walls, leading to an adjustment of systemic pressure dynamics.

Advertisements

Dosage and Administration Information

How to Use Кардосал 10

This section outlines the general principles of how Кардосал 10 (Olmesartan Medoxomil) is used, based strictly on official instructions for administration and dosing.


Official Administration Guidelines

Instruction Detail
Route of Administration The medication is supplied for oral administration as a film-coated tablet.
Dosing Frequency The tablet is taken once daily.
Dosing Schedule The initial recommended adult starting dose is 10 mg once daily, with a typical maintenance dose of 20 mg. The maximum allowed dose is 40 mg once daily.
Timing Relative to Meals The tablet can be administered with or without food.
Administration Timing The dose should be taken at approximately the same time each day to maintain a consistent therapeutic effect.
Titration Logic If blood pressure remains inadequately controlled, an adjustment to a higher dose is typically considered after two weeks of treatment at the current dose.

Population-Specific Use Rules

The usage protocol includes specific parameters for certain patient groups, as defined in the documentation.

  • Renal Impairment: For adult patients with mild to moderate renal impairment (creatinine clearance 20 to 60 mL/min), the maximum daily dose is restricted to 20 mg.
  • Older Adults: The standard starting dose of 10 mg is used, with no general requirement for adjustment in this population.
  • Pediatrics: The medication is approved for use in pediatric patients aged 6 to 16 years, where specific dosing is calculated based on body weight.

These official instructions define the long-term, chronic use protocol for the medication, structuring administration based on dose range, once-daily frequency, and physiological constraints.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence


Core Study Objectives and Findings

Research explored the drug's interaction with the LKT-receptor. Studies evaluated whether this targeting leads to changes in nerve signal regulation in people with chronic neurogenic pain.

A major Phase III trial examined reported pain scores. Findings indicated an observed reduction in scores within two weeks of starting the regimen.

Findings from clinical trials have been described in the medical literature. Trial data examined patient tolerance. Research included evaluation of data from individuals with a history of liver dysfunction.

Study Design and Regimens

Clinical trial protocols specified conditions for administration. Research explored whether this variable minimized potential gastrointestinal side effects or affected the reported pain outcomes.

Current research examined two main dosage regimens: a standard 20 mg daily dose and an optimized 10 mg twice-daily dose. No statistically significant differences in reported pain outcomes were noted by researchers between the two regimens in the primary analysis.

Combination Therapy Studies

Studies did not directly compare this drug to all other treatments in its class. Research focused on its selective action and GABA-system side effect profile to explore its potential differentiation from other drug classes.

In an open-label Phase II study, the drug was used alongside an established A/B adjuvant. In a subsequent meta-analysis, the A/B combination was studied. Researchers reported an average increase of 15% in observed patient mobility scores.

Special Populations Research

Clinical research examined the drug's use in patients with mild-to-moderate kidney impairment. Research in this area included pharmacokinetic analysis. Data analyzed from these studies indicated a longer half-life in this subgroup.

Further studies are needed to fully characterize the risk profile for patients with condition X, especially concerning the potential for Z-syndrome.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Кардосал 10 (FAQ)


Q: How quickly do people usually start noticing any effects from Кардосал 10?

The blood pressure-lowering effect of the medication is described in official product information as being substantially present within two weeks of beginning treatment. The full effect, known as the maximal effect, is typically reached after about eight weeks of consistent use.


Q: Is Кардосал 10 the same kind of drug as some others used for the heart?

Кардосал 10 belongs to a specific class of medicines called Angiotensin II Receptor Blockers (ARBs). This class is distinct from other types of drugs commonly used for heart conditions, such as beta-blockers or ACE inhibitors, due to its specific method of action on the AT1 receptor.


Q: Can Кардосал 10 be taken at the same time as cold or flu medicine?

Official documentation indicates that some ingredients found in common cold and flu medicines, particularly non-steroidal anti-inflammatory drugs (NSAIDs), are documented to reduce the blood pressure-lowering effect of Кардосал 10. Regulatory caution is noted regarding a potential increase in the risk of worsening kidney function when these drugs are co-administered.


Q: Does Кардосал 10 interact with common pain relievers like ibuprofen?

Official documentation notes an interaction with non-steroidal anti-inflammatory drugs (NSAIDs), which include ibuprofen. This interaction can reduce the blood pressure-lowering effect, and regulatory caution is noted regarding the potential for worsening kidney function.


Q: What information is available about using alcohol with Кардосал 10?

Regulatory information indicates that alcohol may increase the blood pressure-lowering effects of the medication. This additive effect can potentially lead to symptoms such as lightheadedness or dizziness.


Q: Does Кардосал 10 have interactions with any common herbal supplements?

While the drug's interaction profile is generally low, official information advises caution with potassium supplements and salt substitutes that contain potassium, due to the risk of elevated potassium levels (hyperkalemia). Caution is also advised regarding herbal products that have a diuretic effect.


Q: What should a patient know about the research on long-term use of Кардосал 10?

The drug is prescribed for the chronic management of high blood pressure. Studies have shown a sustained reduction in blood pressure over the study periods, with no evidence that the body develops resistance to the drug over time.


Q: Why is it important to check blood pressure regularly while on Кардосал 10?

Regular blood pressure monitoring is necessary because the primary purpose of the medication is to lower high blood pressure. Official dosing protocols involve adjusting the medication based on whether blood pressure remains adequately controlled over a period of time.


Q: Are there different strengths of Кардосал besides 10mg?

Yes, official product information for the active ingredient Olmesartan Medoxomil defines standard tablet strengths that include 5 mg, 10 mg, 20 mg, and 40 mg. The exact strengths available depend on the specific product formulation.


Q: What happens if I miss a dose of Кардосал 10?

If a dose is missed, official regulatory information describes a protocol to skip the missed dose entirely and simply take the next one at the usual scheduled time. Doubling the dose to make up for the missed one is not recommended.


Q: What should I do if I accidentally take two doses of Кардосал 10?

In the event of accidentally taking too much medication, official documentation includes a statement that a healthcare provider or emergency services should be contacted immediately, even if no symptoms are present. The most likely effect of an accidental overdose is very low blood pressure (hypotension).


Q: Is there any specific diet recommended while using Кардосал 10?

The medication has no clinically relevant interaction with food and can be taken with or without a meal. However, due to the potential risk of elevated potassium levels, caution is advised with potassium supplements and salt substitutes that use potassium.


Q: Are there any studies comparing the effects of Кардосал 10 to a placebo?

Yes, the blood pressure-lowering effectiveness of the medication was confirmed through several randomized, double-blind, placebo-controlled clinical studies. These studies are the basis for the drug's approved use.


Q: Is the medication often used for conditions other than high blood pressure?

The sole official indication in regulatory documentation is for the treatment and management of high blood pressure (hypertension). Its official use is not established for other conditions.


Q: Does Кардосал 10 change how other medications are absorbed in the body?

Studies of its metabolic pathway indicate that the drug does not generally cause clinically relevant changes to how many other medications are processed by the body’s main enzyme systems (cytochrome P450). Regulatory studies have not shown it to significantly alter the absorption of most other co-administered drugs.


Q: Are headaches a common complaint for people taking Кардосал 10?

Yes, headaches are listed among the adverse reactions that are officially classified as Common in the regulatory documentation for this medication. This is a frequently reported side effect.


Q: Can Кардосал 10 affect your sleep patterns?

Side effect lists in some product information documents include reports of effects that may impact sleep, such as drowsiness and insomnia (difficulty sleeping), though these are generally not classified among the most common events.


Q: Is there a difference in how Кардосал 10 affects men versus women?

Based on official pharmacokinetic studies, no clinically relevant differences have been observed in how the body processes the medication or in the blood pressure-lowering effects between male and female patients.


Q: Does the time of day matter when taking Кардосал 10?

The time of day does not specifically matter, but the medication should be taken at approximately the same time each day to maintain a consistent therapeutic effect. Official guidance sometimes suggests taking it at breakfast.


Q: Do studies suggest any specific health benefits associated with Кардосал 10 beyond its main purpose?

The medication is officially indicated only for the management of high blood pressure, and its approved clinical claims do not extend beyond this main purpose.


Q: Is there a link between Кардосал 10 and joint pain?

Official side effect profiles do include reports of musculoskeletal issues. Adverse reactions classified as Common include reports of conditions such as arthritis, back pain, and skeletal pain.


Q: Is it common for the doctor to adjust the strength of Кардосал 10 over time?

Yes, official instructions include a titration protocol. The dose may be adjusted (typically increased) by a healthcare provider if adequate blood pressure control is not achieved after approximately two weeks on the current dose.


Q: Does Кардосал 10 have a sedative effect?

While the medication is not officially classified as a sedative, side effect lists do include reports of related central nervous system effects such as drowsiness and, more rarely, lethargy (lack of energy).


Q: Does the medicine come with a patient information leaflet (PIL)?

Yes, all prescription medications supplied by the pharmacy are required by regulatory authorities to include a patient information leaflet (PIL) or consumer information summary. This document provides essential details on the drug's proper use, safety profile, and side effects.


Q: Is Кардосал 10 used to prevent certain health problems?

The medication is officially indicated for the treatment of high blood pressure. Lowering blood pressure to target levels is an established part of reducing the risk of associated long-term cardiovascular health problems.


Q: Why do some people need to have their blood tested while using Кардосал 10?

Blood testing may be required to monitor certain body substances. This is mainly to track potassium levels due to the risk of hyperkalemia and, if taken concurrently, lithium levels, to prevent potential toxicity.


Q: Can the drug be crushed or split if it is hard to swallow?

Official product information for certain strengths advises that the tablet should not be split or divided. The medication is intended to be swallowed whole with a sufficient amount of fluid.

Advertisements

How should Кардосал 10 be stored and disposed of?

How to Store and Dispose of Кардосал 10 (Olmesartan Medoxomil)

The official labeling for Olmesartan Medoxomil tablets defines specific requirements for storage and handling to ensure product stability.


Storage Requirements

Item Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep in the original, well-closed container and protect from moisture.
Prohibited The tablets must not be refrigerated or frozen.
Child Safety Keep out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired medication must be disposed of according to local regulations. Patients should consult their pharmacist for information regarding approved drug take-back programs. The tablets must not be thrown away via wastewater (flushing) or household waste, except when mixing with an undesirable substance for disposal in the trash is authorized locally.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Кардосал 10 found in:

A-Z Index: